

A David Paltiel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4722982/a-david-paltiel-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162
papers

7,868
citations

44
h-index

86
g-index

169
ext. papers

9,146
ext. citations

7.3
avg, IF

6.09
L-index

#	Paper	IF	Citations
162	Reliability of patient self-reports to clinician-assigned functional scores of inclusion body myositis.. <i>Journal of the Neurological Sciences</i> , 2022 , 436, 120228	3.2	0
161	Adventures in COVID-19 Policy Modeling: Education Edition. <i>Current HIV/AIDS Reports</i> , 2021 , 1	5.9	0
160	Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1927-e1935	11.6	2
159	Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission. <i>Annals of Internal Medicine</i> , 2021 , 174, 803-810	8	12
158	The Dynamics of Infectious Diseases Associated With Injection Drug Use in Lawrence and Lowell, Massachusetts. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab128	1	0
157	The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m or Greater : A Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , 2021 , 174, 747-757	8	2
156	Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment. <i>Annals of Internal Medicine</i> , 2021 , 174, 568-570	8	36
155	Reducing the Prevalence of Alcohol-Exposed Pregnancies in the United States: A Simulation Modeling Study. <i>Medical Decision Making</i> , 2021 , 272989X211023203	2.5	2
154	Maximizing the Efficiency of Active Case Finding for SARS-CoV-2 Using Bandit Algorithms. <i>Medical Decision Making</i> , 2021 , 41, 970-977	2.5	1
153	Has depression surpassed HIV as a burden to gay and bisexual men's health in the United States? A comparative modeling study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021 , 56, 273-282	4.5	2
152	Adaptive Policies to Balance Health Benefits and Economic Costs of Physical Distancing Interventions during the COVID-19 Pandemic. <i>Medical Decision Making</i> , 2021 , 41, 386-392	2.5	1
151	Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States. <i>Arthritis Care and Research</i> , 2021 ,	4.7	4
150	Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021. <i>Annals of Internal Medicine</i> , 2021 , 174, 1563-1571	8	8
149	Responding to SARS-CoV-2 on College Campuses-Only Beginning to Understand What Works and Why.. <i>JAMA Network Open</i> , 2021 , 4, e2138904	10.4	0
148	COVID-19 Testing and Case Rates and Social Contact Among Residential College Students in Connecticut During the 2020-2021 Academic Year.. <i>JAMA Network Open</i> , 2021 , 4, e2140602	10.4	0
147	Novel microsimulation model of tobacco use behaviours and outcomes: calibration and validation in a US population. <i>BMJ Open</i> , 2020 , 10, e032579	3	1
146	Waiting for Certainty on Covid-19 Antibody Tests - At What Cost?. <i>New England Journal of Medicine</i> , 2020 , 383, e37	59.2	63

145	Has Pre-exposure Prophylaxis Made a Difference at a Population Level? Jury Is Still Out. <i>Clinical Infectious Diseases</i> , 2020 , 71, 3152-3153	11.6	3
144	Budget Impact of Funding an Intensive Diet and Exercise Program for Overweight and Obese Patients With Knee Osteoarthritis. <i>ACR Open Rheumatology</i> , 2020 , 2, 26-36	3.5	4
143	COVID-19 screening strategies that permit the safe re-opening of college campuses 2020 ,		5
142	Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. <i>Addiction</i> , 2020 , 115, 437-450	4.6	9
141	Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis. <i>Annals of Internal Medicine</i> , 2020 , 173, 507-508	8	3
140	Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , 2020 , 172, 583-590	8	19
139	Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States. <i>JAMA Network Open</i> , 2020 , 3, e2016818	10.4	265
138	Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach. <i>Gut</i> , 2020 ,	19.2	4
137	The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. <i>Clinical Infectious Diseases</i> , 2020 , 70, 633-642	11.6	5
136	Quality-Adjusted Life-Years Lost Due to Physical Inactivity in a US Population With Osteoarthritis. <i>Arthritis Care and Research</i> , 2020 , 72, 1349-1357	4.7	6
135	Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. <i>Lancet Infectious Diseases</i> , 2019 , 19, 728-739	25.5	27
134	New USPSTF Guidelines for HIV Screening and Preexposure Prophylaxis (PrEP): Straight A's. <i>JAMA Network Open</i> , 2019 , 2, e195042	10.4	6
133	Cost-Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis. <i>Arthritis Care and Research</i> , 2019 , 71, 855-864	4.7	17
132	Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Cte d'Ivoire: A model-based analysis. <i>PLoS ONE</i> , 2019 , 14, e0219068	3.7	3
131	Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector. <i>PLoS ONE</i> , 2019 , 14, e0218890	3.7	19
130	A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management. <i>Value in Health</i> , 2019 , 22, 1102-1110	3.3	5
129	An Adaptive Approach to Locating Mobile HIV Testing Services. <i>Medical Decision Making</i> , 2018 , 38, 262-273		3
128	The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India. <i>Journal of the International AIDS Society</i> , 2018 , 21, e25085	5.4	9

127	The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. <i>Journal of the International AIDS Society</i> , 2018 , 21, e25096	5.4	13
126	2000. Rapid, Point-of-care Diagnosis of Tuberculosis with Novel Truenat Assay: Cost-Effectiveness and Budgetary Impact Analysis for India—Public Sector. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S582-S582	11.8	78
125	Bayesian adaptive algorithms for locating HIV mobile testing services. <i>BMC Medicine</i> , 2018 , 16, 155	11.4	6
124	Cost-Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis. <i>Arthritis Care and Research</i> , 2017 , 69, 234-242	4.7	25
123	A Flow-Based Model of the HIV Care Continuum in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 75, 548-553	3.1	14
122	Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. <i>Vaccine</i> , 2017 , 35, 3506-3514	4.1	37
121	Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. <i>JAMA Internal Medicine</i> , 2017 , 177, 1613-1621	11.5	66
120	Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. <i>Annals of Internal Medicine</i> , 2017 , 167, 618-629	8	12
119	Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. <i>Open Forum Infectious Diseases</i> , 2017 , 4, ofx081	1	4
118	The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. <i>Journal of Infectious Diseases</i> , 2017 , 216, 798-807	7	14
117	Optimal frequency of rabies vaccination campaigns in Sub-Saharan Africa. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2016 , 283,	4.4	9
116	Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study. <i>Journal of Infectious Diseases</i> , 2016 , 214, 1672-1681	7	72
115	The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. <i>Clinical Infectious Diseases</i> , 2016 , 62, 784-91	11.6	41
114	The Epi-TAF for Tenofovir Disoproxil Fumarate?. <i>Clinical Infectious Diseases</i> , 2016 , 62, 915-8	11.6	15
113	Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1454-1462	11.6	13
112	Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. <i>PLoS ONE</i> , 2016 , 11, e0165614	3.7	12
111	Survival benefits of antiretroviral therapy in Brazil: a model-based analysis. <i>Journal of the International AIDS Society</i> , 2016 , 19, 20623	5.4	13
110	The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa. <i>Annals of Internal Medicine</i> , 2016 , 165, 325-33	8	30

109	Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. <i>Journal of Infectious Diseases</i> , 2016 , 213, 1523-31	7	27
108	The clinical role and cost-effectiveness of long-acting antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2015 , 60, 1102-10	11.6	32
107	Cost-effectiveness of genotype testing for primary resistance in Brazil. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 68, 152-61	3.1	11
106	The lifetime medical cost savings from preventing HIV in the United States. <i>Medical Care</i> , 2015 , 53, 293-301	30.1	71
105	Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. <i>HIV Clinical Trials</i> , 2015 , 16, 207-18		4
104	Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty. <i>Arthritis Care and Research</i> , 2015 , 67, 203-15	4.7	189
103	Demographic and clinical features of inclusion body myositis in North America. <i>Muscle and Nerve</i> , 2015 , 52, 527-33	3.4	17
102	Reducing sexual violence by increasing the supply of toilets in Khayelitsha, South Africa: a mathematical model. <i>PLoS ONE</i> , 2015 , 10, e0122244	3.7	16
101	Defining the Value of Future Research to Identify the Preferred Treatment of Meniscal Tear in the Presence of Knee Osteoarthritis. <i>PLoS ONE</i> , 2015 , 10, e0130256	3.7	11
100	Cost-effectiveness of canine vaccination to prevent human rabies in rural Tanzania. <i>Annals of Internal Medicine</i> , 2014 , 160, 91-100	8	59
99	Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. <i>PLoS ONE</i> , 2014 , 9, e85197	3.7	38
98	Misinterpretation of HIV preexposure prophylaxis findings. <i>Clinical Infectious Diseases</i> , 2014 , 59, 139-41	11.6	
97	The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis. <i>PLoS Medicine</i> , 2014 , 11, e1001725	11.6	48
96	The survival benefits of antiretroviral therapy in South Africa. <i>Journal of Infectious Diseases</i> , 2014 , 209, 491-9	7	28
95	Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Cte d'Ivoire. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 66, 294-302	3.1	6
94	A marginal benefit approach for vaccinating influenza "superspreaders". <i>Medical Decision Making</i> , 2014 , 34, 536-49	2.5	5
93	HIV cure strategies: how good must they be to improve on current antiretroviral therapy?. <i>PLoS ONE</i> , 2014 , 9, e113031	3.7	17
92	Dengue dynamics and vaccine cost-effectiveness in Brazil. <i>Vaccine</i> , 2013 , 31, 3957-61	4.1	34

91	Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. <i>New England Journal of Medicine</i> , 2013 , 369, 1715-25	59.2	98
90	The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. <i>Drug and Alcohol Dependence</i> , 2013 , 128, 90-7	4.9	24
89	Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. <i>Annals of Internal Medicine</i> , 2013 , 158, 84-92	8	100
88	Placing a price on medical device innovation: the example of total knee arthroplasty. <i>PLoS ONE</i> , 2013 , 8, e62709	3.7	27
87	Routine HIV screening in Portugal: clinical impact and cost-effectiveness. <i>PLoS ONE</i> , 2013 , 8, e84173	3.7	24
86	Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. <i>Medical Decision Making</i> , 2012 , 32, 678-89	2.5	158
85	Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. <i>Value in Health</i> , 2012 , 15, 835-42	3.3	371
84	Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2. <i>Value in Health</i> , 2012 , 15, 804-11	3.3	129
83	The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. <i>Clinical Infectious Diseases</i> , 2012 , 54, 1504-13	11.6	75
82	What is a modest public health impact?. <i>Archives of Internal Medicine</i> , 2012 , 172, 521-2; author reply 522-3		1
81	Impact of program scale and indirect effects on the cost-effectiveness of vaccination programs. <i>Medical Decision Making</i> , 2012 , 32, 442-6	2.5	7
80	Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. <i>Medical Decision Making</i> , 2012 , 32, 722-32	2.5	402
79	Home HIV testing: good news but not a game changer. <i>Annals of Internal Medicine</i> , 2012 , 157, 744-6	8	20
78	The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results. <i>Vaccine</i> , 2011 , 29, 6107-12	4.1	17
77	Dengue vector control strategies in an urban setting: an economic modelling assessment. <i>Lancet, The</i> , 2011 , 377, 1673-80	40	97
76	Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department. <i>PLoS ONE</i> , 2011 , 6, e25575	3.7	10
75	The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, 26-35	3.1	51
74	Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. <i>Annals of Internal Medicine</i> , 2011 , 154, 217-26	8	167

73	Scaling up circumcision programs in Southern Africa: the potential impact of gender disparities and changes in condom use behaviors on heterosexual HIV transmission. <i>AIDS and Behavior</i> , 2011 , 15, 938-48	4.3	20
72	Projected survival gains from revising state laws requiring written opt-in consent for HIV testing. <i>Journal of General Internal Medicine</i> , 2011 , 26, 661-7	4	7
71	Medical device innovation--is "better" good enough?. <i>New England Journal of Medicine</i> , 2011 , 365, 1464-9	9.2	12
70	Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis. <i>Value in Health</i> , 2010 , 13, 893-902	3.3	20
69	Routine HIV screening in France: clinical impact and cost-effectiveness. <i>PLoS ONE</i> , 2010 , 5, e13132	3.7	72
68	Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. <i>Clinical Infectious Diseases</i> , 2010 , 51, 392-400	11.6	88
67	Price, performance, and the FDA approval process: the example of home HIV testing. <i>Medical Decision Making</i> , 2010 , 30, 217-23	2.5	13
66	Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. <i>PLoS Medicine</i> , 2010 , 7, e1000382	11.6	62
65	Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Cote d'Ivoire appraisal. <i>PLoS Medicine</i> , 2009 , 6, e1000173	11.6	62
64	HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. <i>Clinical Infectious Diseases</i> , 2009 , 48, 806-15	11.6	204
63	Medical decision making in patients with knee pain, meniscal tear, and osteoarthritis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1531-8		6
62	Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2009 , 49, 1570-8	11.6	149
61	HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 310-6	3.1	41
60	Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. <i>Archives of Internal Medicine</i> , 2009 , 169, 1113-21; discussion 1121-2		388
59	When to start antiretroviral therapy in resource-limited settings. <i>Annals of Internal Medicine</i> , 2009 , 151, 157-66	8	101
58	Modeling the potential impact of a prescription drug copayment increase on the adult asthmatic medicaid population. <i>Value in Health</i> , 2008 , 11, 110-8	3.3	2
57	Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. <i>Journal of Infectious Diseases</i> , 2008 , 197, 1324-32	7	53
56	Social costs of robbery and the cost-effectiveness of substance abuse treatment. <i>Health Economics (United Kingdom)</i> , 2008 , 17, 927-46	2.4	26

55	Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. <i>Journal of Allergy and Clinical Immunology</i> , 2007 , 120, 1146-52	11.5	91
54	The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. <i>Clinical Infectious Diseases</i> , 2007 , 44, 1115-22	11.6	44
53	Cost-effectiveness of HIV testing and treatment in the United States. <i>Clinical Infectious Diseases</i> , 2007 , 45 Suppl 4, S248-54	11.6	89
52	Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 46, 78-90	3.1	22
51	Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 43 Suppl 1, S113-8 ^{3,1}		37
50	Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma. <i>Pediatrics</i> , 2006 , 118, e347-55	7.4	72
49	Fact, fiction, and fairness: resource allocation under the Ryan White CARE Act. <i>Health Affairs</i> , 2006 , 25, 1103-12	7	12
48	The survival benefits of AIDS treatment in the United States. <i>Journal of Infectious Diseases</i> , 2006 , 194, 11-9	7	49 ⁸
47	Cost-effectiveness of inhaled steroids in asthma: impact of effect on bone mineral density. <i>Journal of Allergy and Clinical Immunology</i> , 2006 , 117, 359-66	11.5	17
46	Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. <i>Annals of Internal Medicine</i> , 2006 , 145, 797-806	8	147
45	Rapid HIV testing at home: does it solve a problem or create one?. <i>Annals of Internal Medicine</i> , 2006 , 145, 459-62	8	58
44	Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. <i>American Journal of Medicine</i> , 2005 , 118, 292-300	2.4	88
43	Cost advantage of dual-chamber versus single-chamber cardioverter-defibrillator implantation. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 850-7	15.1	29
42	Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. <i>Medical Decision Making</i> , 2005 , 25, 321-9	2.5	23
41	Expanded screening for HIV in the United States--an analysis of cost-effectiveness. <i>New England Journal of Medicine</i> , 2005 , 352, 586-95	59.2	43 ⁶
40	Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 39, 69-77	3.1	31
39	Cost-effectiveness of HIV screening for incarcerated pregnant women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 38, 163-73	3.1	19
38	An Asthma Policy Model 2005 , 659-693		1

37	Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2005 , 10, 41-52	1.6	8
36	A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. <i>Chest</i> , 2004 , 126, 1875-82	5.3	105
35	Quality of life after aortic valve replacement with tissue and mechanical implants. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2004 , 128, 266-72	1.5	37
34	Association between preference-based health-related quality of life and asthma severity. <i>Annals of Allergy, Asthma and Immunology</i> , 2004 , 92, 329-34	3.2	25
33	A therapeutic HIV vaccine: how good is good enough?. <i>Vaccine</i> , 2004 , 22, 4044-53	4.1	19
32	Economic costs of influenza-related work absenteeism. <i>Value in Health</i> , 2003 , 6, 107-15	3.3	69
31	Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. <i>American Journal of Medicine</i> , 2003 , 115, 632-41	2.4	87
30	Prophylaxis for human immunodeficiency virus-related <i>Pneumocystis carinii</i> pneumonia: using simulation modeling to inform clinical guidelines. <i>Archives of Internal Medicine</i> , 2002 , 162, 921-8		34
29	Impact of site of care, race, and Hispanic ethnicity on medication use for childhood asthma. <i>Pediatrics</i> , 2002 , 109, E1	7.4	118
28	AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States. <i>Clinical Infectious Diseases</i> , 2002 , 35, 606-10	11.6	14
27	Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 31, 27-37	3.1	29
26	The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 30, 421-8	3.1	21
25	State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards. <i>Medical Care</i> , 2002 , 40, 429-41	3.1	21
24	Task force #2--the cost of prevention: can we afford it? Can we afford not to do it? 33rd Bethesda Conference. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 603-15	15.1	17
23	A novel approach to defining the relationship between lung function and symptom status in asthma. <i>Journal of Clinical Epidemiology</i> , 2002 , 55, 11-8	5.7	16
22	Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2002 , 7, 257-66	1.6	14
21	Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2002 , 7, 257-266	1.6	19
20	Model-Based Drug Evaluation in Chronic Disease: Promise, Pitfalls, and Positioning. <i>Drug Information Journal</i> , 2001 , 35, 131-139		3

19	Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. <i>Clinical Infectious Diseases</i> , 2001 , 32, 783-93	11.6	25
18	Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. <i>International Journal of Epidemiology</i> , 2001 , 30, 864-71	7.8	49
17	The cost effectiveness of combination antiretroviral therapy for HIV disease. <i>New England Journal of Medicine</i> , 2001 , 344, 824-31	59.2	388
16	Use of health services by insurance status among children with asthma. <i>Medical Care</i> , 2001 , 39, 1065-74	3.1	48
15	Evaluation of therapeutic strategies: a new method for balancing risk and benefit. <i>Value in Health</i> , 2000 , 3, 12-22	3.3	4
14	Five minutes with the Governor. <i>Medical Decision Making</i> , 2000 , 20, 239-42	2.5	3
13	THE COST-EFFECTIVENESS OF PROPHYLAXIS FOR MYCOBACTERIUM AVIUM COMPLEX IN AIDS. <i>International Journal of Technology Assessment in Health Care</i> , 1999 , 15, 531-547	1.8	8
12	Cost effectiveness of prophylaxis for opportunistic infections in AIDS. An overview and methodological discussion. <i>Pharmacoeconomics</i> , 1998 , 14, 165-74	4.4	11
11	A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. <i>Medical Decision Making</i> , 1998 , 18, S93-105	2.5	39
10	Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. <i>Medical Decision Making</i> , 1997 , 17, 483-9	2.5	92
9	The cost-effectiveness of HIV testing: accounting for differential participation rates. <i>Medical Decision Making</i> , 1997 , 17, 490-5	2.5	7
8	The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. <i>Medical Decision Making</i> , 1997 , 17, 373-81	2.5	36
7	Why training is the key to successful guideline implementation. <i>Pharmacoeconomics</i> , 1997 , 12, 297-302	4.4	4
6	Economic evaluation of HIV testing among intravenous drug users. An analytic framework and its application to Italy. <i>International Journal of Technology Assessment in Health Care</i> , 1996 , 12, 336-57	1.8	10
5	The FDA and regulation of cost-effectiveness claims. <i>Health Affairs</i> , 1996 , 15, 54-71	0	21
4	Making Health Policy Decisions: Is Human Instinct Rational? Is Rational Choice Human?. <i>Chance</i> , 1996 , 9, 34-39	1	7
3	Model-based estimates of deaths averted and cost per life saved by scaling-up mRNA COVID-19 vaccination in low and lower-middle income countries in the COVID-19 Omicron variant era		2
2	Assessing COVID prevention strategies to permit the safe opening of college campuses in fall 2021		2

1 COVID-19 in Connecticut institutions of higher education during the 2020-2021 academic year

2